Entresto

Advertisements champion Entresto as a phenomenal treatment for heart failure capable of reducing cardiovascular death and heart related hospitalization. Many peculiarities exist in the study leading to FDA approval. It was principally conducted in Eastern European countries, Russia, the Philippines, Venezuela, Brazil, Mexico and India. Only 5% of the patients resided in the United States. Actually Entresto basically combines the anti-hypertensive Diovan with a new compound Sacubirtil. Entresto with the maximum amount of Diovan was evaluated against a modest dose of another drug for high blood pressure rather than Diovan. So all of the benefits might actually stem from the Diovan component. Generic Diovan or valsartan costs less than $25 a month. Entresto’s cash price of $6000 a year or about $16 a day caused insurance companies initial hesitation which led to a lengthy authorization process. Due to the high drop-out rate, the benefits may much less than reported. Additionally it apparently works only in the milder forms of heart failure.